Kinoxis Therapeutics has raised $6.8M in seed funding from Main Sequence, capital that will support the Australian clinical-stage biotech's work on therapies for neuropsychiatric and central nervous system disorders.
The company's lead candidate, KNX100, is a short-acting small-molecule inhibitor of ALOX15, a regulator of neuroinflammation and neural excitability in the brain. It's currently in a Phase 2 trial in Australia called CARES-X, testing its safety, tolerability, and efficacy in patients with agitation associated with dementia. Kinoxis is also advancing KNX101, a longer-acting ALOX15 inhibitor aimed at acute and chronic pain and chronic agitation.


















